瑞帕霉素释放支架治疗再狭窄患者是安全的

 
一项最新研究报道瑞帕霉素释放支架植入手术，用于治疗那些接受过金属支架治疗又发生再狭窄的患者，是十分安全有效的。

意大利San Donato医院(Arezzo, Italy)评估了瑞帕霉素释放支架植入手术患者的成功率，共计244例患者未经选择的首次支架植入之后，在原来冠状动脉或者隐静脉移植发生再狭窄(ISR)，被入选了TRUE临床研究。

瑞帕霉素支架被成功植入了病变区域。在9个月的随访中，4例患者(1.6%)死亡，4例出现心肌梗塞(MI)。缺血驱动的目标血管再形成(TVR)见于12例患者(4.9%)，而总体无事件生存的患者有227例(93%)。尽管9个月的随访中计划对所有患者进行血管造影检查，只有150例(62%)患者完成了检查，在这些患者中有13例(8.7%)发生了再狭窄。
 
Sirolimus Stent Safe for Restenosis Patients
 
A new study reports that sirolimus-eluting stent implantation appears to be safe and effective in restenosis patients originally treated with bare metal stents.

Researchers at San Donato Hospital (Arezzo, Italy) evaluated the success of implanting sirolimus-eluting stents in 244 unselected patients with first-time in-stent restenosis (ISR) in a native coronary artery or saphenous vein graft, who were enrolled in the Tuscany Registry of sirolimus for Unselected in-stent restenosis (TRUE) study.

The sirolimus stents were successfully implanted in all lesions. At nine-month follow-up, four patients (1.6%) had died and four had a myocardial infarction (MI). Ischemia-driven target vessel revascularization (TVR) was seen in 12 patients (4.9%), for a cumulative event-free survival of 227 patients (93%). Although nine-month follow-up angiography was planned in all patients, only 150 (62%) patients completed it, and restenosis was present in 13 (8.7%) of these patients.